Research
Hormonal
The long-acting GIPR agonist LY3537021 induced a mean body weight loss of 3.14 kg in participants with T2D compared to 0.36 kg in the placebo group at day 57 (p < 0.05).
LY3537021 may be an effective treatment option for weight loss in patients with T2D.
StrongSupportsmedium confidence
For example, participants with T2D treated with 25 mg of LY3537021 lost a mean of 3.14 kg of body weight compared with 0.36 kg in the placebo group (p < 0.05) at day 57.
Why this rating
Based on the phase 1 randomized controlled trial design.
Source
Long-acting GIPR agonist LY3537021 reduces body weight and fasting blood glucose in patients with T2D: Preclinical development and phase 1 randomized ascending dose studies
William C. Roell et al. · Molecular Metabolism · 2025
rctCited 2×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →